Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.
The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. The ...
Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a ...
Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over ...
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and ...
StockStory.org on MSN
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health shares skyrocket, what you need to know
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a ...
LNK01006 reflects Lynk Pharmaceuticals' medicinal chemistry expertise, incorporating a highly optimized scaffold engineered for target selectivity, metabolic stability, and CNS penetration. "We are ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results